Analysis of Reportable Segments
Danaher Corp. operates in 3 segments: Biotechnology; Life Sciences; and Diagnostics.
Segment Profit Margin
Danaher Corp., profit margin by reportable segment
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Biotechnology | 24.93% | 26.62% | 34.35% | 35.87% | 20.51% |
| Life Sciences | 11.99% | 16.93% | 20.10% | 20.24% | 18.34% |
| Diagnostics | 26.82% | 25.12% | 31.67% | 23.50% | 20.78% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | Biotechnology | Biotechnology segment profit margin ratio deteriorated from 2022 to 2023 and from 2023 to 2024. |
| Life Sciences | Life Sciences segment profit margin ratio deteriorated from 2022 to 2023 and from 2023 to 2024. | |
| Diagnostics | Diagnostics segment profit margin ratio deteriorated from 2022 to 2023 but then slightly improved from 2023 to 2024. |
Segment Profit Margin: Biotechnology
Danaher Corp.; Biotechnology; segment profit margin calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Operating profit | 1,685) | 1,909) | 3,008) | 3,074) | 1,082) |
| Sales | 6,759) | 7,172) | 8,758) | 8,570) | 5,276) |
| Segment Profitability Ratio | |||||
| Segment profit margin1 | 24.93% | 26.62% | 34.35% | 35.87% | 20.51% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment profit margin = 100 × Operating profit ÷ Sales
= 100 × 1,685 ÷ 6,759 = 24.93%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | Biotechnology | Biotechnology segment profit margin ratio deteriorated from 2022 to 2023 and from 2023 to 2024. |
Segment Profit Margin: Life Sciences
Danaher Corp.; Life Sciences; segment profit margin calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Operating profit | 879) | 1,209) | 1,414) | 1,293) | 972) |
| Sales | 7,329) | 7,141) | 7,036) | 6,388) | 5,300) |
| Segment Profitability Ratio | |||||
| Segment profit margin1 | 11.99% | 16.93% | 20.10% | 20.24% | 18.34% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment profit margin = 100 × Operating profit ÷ Sales
= 100 × 879 ÷ 7,329 = 11.99%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | Life Sciences | Life Sciences segment profit margin ratio deteriorated from 2022 to 2023 and from 2023 to 2024. |
Segment Profit Margin: Diagnostics
Danaher Corp.; Diagnostics; segment profit margin calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Operating profit | 2,625) | 2,406) | 3,436) | 2,313) | 1,538) |
| Sales | 9,787) | 9,577) | 10,849) | 9,844) | 7,403) |
| Segment Profitability Ratio | |||||
| Segment profit margin1 | 26.82% | 25.12% | 31.67% | 23.50% | 20.78% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment profit margin = 100 × Operating profit ÷ Sales
= 100 × 2,625 ÷ 9,787 = 26.82%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | Diagnostics | Diagnostics segment profit margin ratio deteriorated from 2022 to 2023 but then slightly improved from 2023 to 2024. |
Segment Return on Assets (Segment ROA)
Danaher Corp., ROA by reportable segment
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Biotechnology | 4.87% | 5.10% | 8.01% | 8.06% | 2.77% |
| Life Sciences | 3.79% | 5.09% | 8.05% | 6.54% | 9.89% |
| Diagnostics | 18.48% | 16.53% | 23.34% | 15.36% | 10.22% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment ROA | Biotechnology | Biotechnology segment ROA deteriorated from 2022 to 2023 and from 2023 to 2024. |
| Life Sciences | Life Sciences segment ROA deteriorated from 2022 to 2023 and from 2023 to 2024. | |
| Diagnostics | Diagnostics segment ROA deteriorated from 2022 to 2023 but then slightly improved from 2023 to 2024. |
Segment ROA: Biotechnology
Danaher Corp.; Biotechnology; segment ROA calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Operating profit | 1,685) | 1,909) | 3,008) | 3,074) | 1,082) |
| Identifiable assets | 34,605) | 37,421) | 37,536) | 38,118) | 39,086) |
| Segment Profitability Ratio | |||||
| Segment ROA1 | 4.87% | 5.10% | 8.01% | 8.06% | 2.77% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment ROA = 100 × Operating profit ÷ Identifiable assets
= 100 × 1,685 ÷ 34,605 = 4.87%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment ROA | Biotechnology | Biotechnology segment ROA deteriorated from 2022 to 2023 and from 2023 to 2024. |
Segment ROA: Life Sciences
Danaher Corp.; Life Sciences; segment ROA calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Operating profit | 879) | 1,209) | 1,414) | 1,293) | 972) |
| Identifiable assets | 23,211) | 23,730) | 17,572) | 19,768) | 9,833) |
| Segment Profitability Ratio | |||||
| Segment ROA1 | 3.79% | 5.09% | 8.05% | 6.54% | 9.89% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment ROA = 100 × Operating profit ÷ Identifiable assets
= 100 × 879 ÷ 23,211 = 3.79%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment ROA | Life Sciences | Life Sciences segment ROA deteriorated from 2022 to 2023 and from 2023 to 2024. |
Segment ROA: Diagnostics
Danaher Corp.; Diagnostics; segment ROA calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Operating profit | 2,625) | 2,406) | 3,436) | 2,313) | 1,538) |
| Identifiable assets | 14,204) | 14,552) | 14,722) | 15,054) | 15,042) |
| Segment Profitability Ratio | |||||
| Segment ROA1 | 18.48% | 16.53% | 23.34% | 15.36% | 10.22% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment ROA = 100 × Operating profit ÷ Identifiable assets
= 100 × 2,625 ÷ 14,204 = 18.48%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment ROA | Diagnostics | Diagnostics segment ROA deteriorated from 2022 to 2023 but then slightly improved from 2023 to 2024. |
Segment Asset Turnover
Danaher Corp., asset turnover by reportable segment
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Biotechnology | 0.20 | 0.19 | 0.23 | 0.22 | 0.13 |
| Life Sciences | 0.32 | 0.30 | 0.40 | 0.32 | 0.54 |
| Diagnostics | 0.69 | 0.66 | 0.74 | 0.65 | 0.49 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
| Segment activity ratio | Reportable segment | The company |
|---|---|---|
| Segment asset turnover | Biotechnology | Biotechnology segment asset turnover ratio deteriorated from 2022 to 2023 but then slightly improved from 2023 to 2024. |
| Life Sciences | Life Sciences segment asset turnover ratio deteriorated from 2022 to 2023 but then slightly improved from 2023 to 2024. | |
| Diagnostics | Diagnostics segment asset turnover ratio deteriorated from 2022 to 2023 but then slightly improved from 2023 to 2024. |
Segment Asset Turnover: Biotechnology
Danaher Corp.; Biotechnology; segment asset turnover calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Sales | 6,759) | 7,172) | 8,758) | 8,570) | 5,276) |
| Identifiable assets | 34,605) | 37,421) | 37,536) | 38,118) | 39,086) |
| Segment Activity Ratio | |||||
| Segment asset turnover1 | 0.20 | 0.19 | 0.23 | 0.22 | 0.13 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment asset turnover = Sales ÷ Identifiable assets
= 6,759 ÷ 34,605 = 0.20
| Segment activity ratio | Reportable segment | The company |
|---|---|---|
| Segment asset turnover | Biotechnology | Biotechnology segment asset turnover ratio deteriorated from 2022 to 2023 but then slightly improved from 2023 to 2024. |
Segment Asset Turnover: Life Sciences
Danaher Corp.; Life Sciences; segment asset turnover calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Sales | 7,329) | 7,141) | 7,036) | 6,388) | 5,300) |
| Identifiable assets | 23,211) | 23,730) | 17,572) | 19,768) | 9,833) |
| Segment Activity Ratio | |||||
| Segment asset turnover1 | 0.32 | 0.30 | 0.40 | 0.32 | 0.54 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment asset turnover = Sales ÷ Identifiable assets
= 7,329 ÷ 23,211 = 0.32
| Segment activity ratio | Reportable segment | The company |
|---|---|---|
| Segment asset turnover | Life Sciences | Life Sciences segment asset turnover ratio deteriorated from 2022 to 2023 but then slightly improved from 2023 to 2024. |
Segment Asset Turnover: Diagnostics
Danaher Corp.; Diagnostics; segment asset turnover calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Sales | 9,787) | 9,577) | 10,849) | 9,844) | 7,403) |
| Identifiable assets | 14,204) | 14,552) | 14,722) | 15,054) | 15,042) |
| Segment Activity Ratio | |||||
| Segment asset turnover1 | 0.69 | 0.66 | 0.74 | 0.65 | 0.49 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment asset turnover = Sales ÷ Identifiable assets
= 9,787 ÷ 14,204 = 0.69
| Segment activity ratio | Reportable segment | The company |
|---|---|---|
| Segment asset turnover | Diagnostics | Diagnostics segment asset turnover ratio deteriorated from 2022 to 2023 but then slightly improved from 2023 to 2024. |
Segment Capital Expenditures to Depreciation
Danaher Corp., capital expenditures to depreciation by reportable segment
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Biotechnology | 0.44 | 0.41 | 0.40 | 0.36 | 0.22 |
| Life Sciences | 0.53 | 0.57 | 0.61 | 0.55 | 0.47 |
| Diagnostics | 0.94 | 0.95 | 0.65 | 1.05 | 0.74 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
| Segment financial ratio | Reportable segment | The company |
|---|---|---|
| Segment capital expenditures to depreciation | Biotechnology | Biotechnology segment capital expenditures to depreciation ratio improved from 2022 to 2023 and from 2023 to 2024. |
| Life Sciences | Life Sciences segment capital expenditures to depreciation ratio deteriorated from 2022 to 2023 and from 2023 to 2024. | |
| Diagnostics | Diagnostics segment capital expenditures to depreciation ratio improved from 2022 to 2023 but then slightly deteriorated from 2023 to 2024. |
Segment Capital Expenditures to Depreciation: Biotechnology
Danaher Corp.; Biotechnology; segment capital expenditures to depreciation calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Capital expenditures, gross | 447) | 417) | 405) | 385) | 169) |
| Depreciation and amortization of intangible assets | 1,014) | 1,026) | 1,002) | 1,059) | 761) |
| Segment Financial Ratio | |||||
| Segment capital expenditures to depreciation1 | 0.44 | 0.41 | 0.40 | 0.36 | 0.22 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment capital expenditures to depreciation = Capital expenditures, gross ÷ Depreciation and amortization of intangible assets
= 447 ÷ 1,014 = 0.44
| Segment financial ratio | Reportable segment | The company |
|---|---|---|
| Segment capital expenditures to depreciation | Biotechnology | Biotechnology segment capital expenditures to depreciation ratio improved from 2022 to 2023 and from 2023 to 2024. |
Segment Capital Expenditures to Depreciation: Life Sciences
Danaher Corp.; Life Sciences; segment capital expenditures to depreciation calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Capital expenditures, gross | 391) | 320) | 325) | 210) | 137) |
| Depreciation and amortization of intangible assets | 743) | 558) | 531) | 382) | 292) |
| Segment Financial Ratio | |||||
| Segment capital expenditures to depreciation1 | 0.53 | 0.57 | 0.61 | 0.55 | 0.47 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment capital expenditures to depreciation = Capital expenditures, gross ÷ Depreciation and amortization of intangible assets
= 391 ÷ 743 = 0.53
| Segment financial ratio | Reportable segment | The company |
|---|---|---|
| Segment capital expenditures to depreciation | Life Sciences | Life Sciences segment capital expenditures to depreciation ratio deteriorated from 2022 to 2023 and from 2023 to 2024. |
Segment Capital Expenditures to Depreciation: Diagnostics
Danaher Corp.; Diagnostics; segment capital expenditures to depreciation calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Capital expenditures, gross | 550) | 546) | 382) | 644) | 447) |
| Depreciation and amortization of intangible assets | 586) | 577) | 590) | 614) | 602) |
| Segment Financial Ratio | |||||
| Segment capital expenditures to depreciation1 | 0.94 | 0.95 | 0.65 | 1.05 | 0.74 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment capital expenditures to depreciation = Capital expenditures, gross ÷ Depreciation and amortization of intangible assets
= 550 ÷ 586 = 0.94
| Segment financial ratio | Reportable segment | The company |
|---|---|---|
| Segment capital expenditures to depreciation | Diagnostics | Diagnostics segment capital expenditures to depreciation ratio improved from 2022 to 2023 but then slightly deteriorated from 2023 to 2024. |
Sales
Danaher Corp., sales by reportable segment
US$ in millions
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Biotechnology | 6,759) | 7,172) | 8,758) | 8,570) | 5,276) |
| Life Sciences | 7,329) | 7,141) | 7,036) | 6,388) | 5,300) |
| Diagnostics | 9,787) | 9,577) | 10,849) | 9,844) | 7,403) |
| Environmental & Applied Solutions | —) | —) | 4,828) | 4,651) | 4,305) |
| Total | 23,875) | 23,890) | 31,471) | 29,453) | 22,284) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
Operating profit
Danaher Corp., operating profit by reportable segment
US$ in millions
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Biotechnology | 1,685) | 1,909) | 3,008) | 3,074) | 1,082) |
| Life Sciences | 879) | 1,209) | 1,414) | 1,293) | 972) |
| Diagnostics | 2,625) | 2,406) | 3,436) | 2,313) | 1,538) |
| Environmental & Applied Solutions | —) | —) | 1,135) | 1,054) | 979) |
| Other | (326) | (322) | (305) | (269) | (340) |
| Total | 4,863) | 5,202) | 8,688) | 7,465) | 4,231) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
Depreciation and amortization of intangible assets
Danaher Corp., depreciation and amortization of intangible assets by reportable segment
US$ in millions
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Biotechnology | 1,014) | 1,026) | 1,002) | 1,059) | 761) |
| Life Sciences | 743) | 558) | 531) | 382) | 292) |
| Diagnostics | 586) | 577) | 590) | 614) | 602) |
| Environmental & Applied Solutions | —) | —) | 90) | 106) | 110) |
| Other | 9) | 5) | 9) | 7) | 10) |
| Total | 2,352) | 2,166) | 2,222) | 2,168) | 1,775) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
Identifiable assets
Danaher Corp., identifiable assets by reportable segment
US$ in millions
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Biotechnology | 34,605) | 37,421) | 37,536) | 38,118) | 39,086) |
| Life Sciences | 23,211) | 23,730) | 17,572) | 19,768) | 9,833) |
| Diagnostics | 14,204) | 14,552) | 14,722) | 15,054) | 15,042) |
| Environmental & Applied Solutions | —) | —) | 4,797) | 4,882) | 5,083) |
| Other | 5,522) | 8,785) | 9,723) | 5,362) | 7,117) |
| Total | 77,542) | 84,488) | 84,350) | 83,184) | 76,161) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
Capital expenditures, gross
Danaher Corp., capital expenditures, gross by reportable segment
US$ in millions
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Biotechnology | 447) | 417) | 405) | 385) | 169) |
| Life Sciences | 391) | 320) | 325) | 210) | 137) |
| Diagnostics | 550) | 546) | 382) | 644) | 447) |
| Environmental & Applied Solutions | —) | —) | 34) | 54) | 36) |
| Other | 4) | 100) | 6) | 1) | 2) |
| Total | 1,392) | 1,383) | 1,152) | 1,294) | 791) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).